Adelene Q. Perkins has served as our Chief Executive Officer since January 2010,
our President between October 2008 and January 2017, our Chief Business Officer
from October 2008 through December 2009 and our Executive Vice President and Chief
Business Officer between September 2006 and October 2008. Ms. Perkins served as
Executive Vice President of IPI from February 2006 until its merger with DPI in
September 2006 and Chief Business Officer of IPI from June 2002 until the DPI
merger. Prior to joining IPI, Ms. Perkins served as Vice President of Business
and Corporate Development of TransForm Pharmaceuticals, Inc., a private pharmaceutical
company, from 2000 to 2002. From 1992 to 1999, Ms. Perkins held various positions
at Genetics Institute, most recently serving as Vice President of Emerging Business
and General Manager of the DiscoverEase® business unit. Ms. Perkins has served
as a director of the Biotechnology Industry Organization since 2012, a director
of Project Hope, a not-for-profit social services company since 2013, a director
of the Massachusetts Life Sciences Center, a quasi-public agency of the Commonwealth
of Massachusetts, since 2014, a director of the Massachusetts Biotechnology Council,
a not-for-profit organization, since 2014, and a director of Padlock Therapeutics,
a privately held biopharmaceutical company since 2015. From 1985 to 1992, Ms.
Perkins held a variety of positions at Bain & Company, a strategy consulting
firm. Ms. Perkins received a B.S. in Chemical Engineering from Villanova University
and an M.B.A. from Harvard Business School.
Lawrence E. Bloch, M.D., J.D., has served as our President since January 2017,
and our Executive Vice President, Chief Financial Officer and Chief Business
Officer from July 2012 to December 2016. Prior to joining Infinity, Dr. Bloch
served as Chief Executive Officer of NeurAxon, Inc., a privately held biopharmaceutical
company, from 2007 to 2011. Previously, he served as Chief Financial Officer
and Chief Business Officer of NitroMed, Inc., a publicly held biopharmaceutical
company, from 2004 to 2006. From 2000 to 2004, Dr. Bloch served as Chief Financial
Officer, and from 1999 to 2002 as Vice President, Business Development, of Applied
Molecular Evolution, Inc., a publicly held biopharmaceutical company. Dr. Bloch
began his career as an emergency medicine resident physician at Massachusetts
General Hospital and Brigham & Woman’s Hospital. Dr. Bloch has served
as director of NeurAxon, Inc., a privately held biopharmaceutical company, from
2007 to 2011. He holds a J.D. from Harvard Law School, an M.D. from Harvard
Medical School and an M.B.A. from Harvard Business School.
Jeffery L. Kutok, M.D., Ph.D., has served as our Senior Vice President and
Chief Scientific Officer since February 2017, our Vice President of Biology
and Translational Science from August 2013 to February 2017, our Senior Director
of Biology and Translational Science from August 2012 to August 2013, our Senior
Director of Molecular Pathology from March 2012 to August 2012, and our Director
of Molecular Pathology from January 2011 to March 2012. Prior to joining Infinity,
Dr. Kutok was an associate professor of pathology at Harvard Medical School
and Brigham and Women’s Hospital. His laboratory focused on translational
medicine research and biomarker identification in cancer, and he is an author
on over 190 journal articles, reviews and book chapters. Dr. Kutok is board
certified in Anatomic Pathology and Hematology and had clinical duties in Hematopathology
and Molecular Diagnostics at Brigham and Women’s Hospital. Dr. Kutok received
his B.S. in biology and his M.D., Ph.D. in medicine and molecular pathology
from the State University of New York at Stony Brook. His Ph.D. was earned working
in the laboratory of Dr. Barry Coller, M.D. in the field of platelet pathobiology.
He was also a post-doctoral fellow at Harvard University in the laboratory of
Dr. Gary Gilliland, M.D., Ph.D.
Seth A. Tasker, J.D. has served as our Vice President, General Counsel and
Secretary since July 2016, our Deputy General Counsel between March 2015 and
July 2016, our Associate General Counsel between March 2013 and March 2015,
our Assistant General Counsel between March 2010 and March 2013, and our Corporate
Counsel between March 2008 and March 2010. Prior to joining Infinity, Mr. Tasker
served in varying levels of responsibility in the legal function at Surface
Logix, Inc., a privately hely biopharmaceutical company, from 2001 to 2008.
Mr. Tasker holds a B.S. in Microbiology from the University of Vermont, a J.D.
from Suffolk University Law School, and an M.B.A. from Suffolk University Sawyer
School of Management.
Infinity Pharmaceuticals Inc currently has 41 employees.
